European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Archives of Neurology

• Publication date

  2004-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHNEUR.61.9.1409PMID 15364687
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation

  2004cited by this paper
• The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS

  2003influential reference
• Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: Consensus report of the White Matter Study Group

  2002influential reference
• MRI techniques to monitor MS evolution: The present and the future

  2002cited by this paper
• A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis

  2001cited by this paper
• Scan-rescan variation of measures derived from brain magnetization transfer ratio histograms obtained in healthy volunteers by use of a semi-interleaved magnetization transfer sequence.

  2001cited by this paper
• Immunopathology of secondary‐progressive multiple sclerosis

  2001cited by this paper
• The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis

  2000cited by this paper
• The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

  2000cited by this paper
• Magnetization transfer imaging to monitor the evolution of MS

  2000influential reference
• Whole brain volume changes in patients with progressive MS treated with cladribine

  2000cited by this paper
• Reproducibility of magnetization transfer ratio histogram-derived measures of the brain in healthy volunteers.

  2000cited by this paper
• ESIMS - An Ongoing Clinical Trial in Secondary Progressive Multiple Sclerosis

  2000cited by this paper
• Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis.

  1999cited by this paper
• Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.

  1999cited by this paper
• Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability

  1999influential reference
• Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial

  1999cited by this paper
• Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H

  1999cited by this paper
• Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

  1998cited by this paper
• Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR.

  1998cited by this paper
• Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses

  1998cited by this paper
• Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images

  1997cited by this paper
• A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results

  1997cited by this paper
• Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study

  1997cited by this paper
• Quantitative volumetric magnetization transfer analysis in multiple sclerosis: Estimation of macroscopic and microscopic disease burden

  1996cited by this paper
• Intravenous immunoglobulin treatment in multiple sclerosis.

  1995cited by this paper
• Passage of intravenous immunoglobulin and interaction with the CNS.

  1994cited by this paper
• Immunoglobulins promote remyelination in the central nervous system

  1990cited by this paper

• Ginsenoside Rb3 represses CPZ-induced demyelination and neuroinflammation by inhibiting TRAF6 K63 ubiquitination.

  2025cites this paper
• Quantitative magnetization transfer imaging in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis

  2022cites this paper
• Predictive MRI Biomarkers in MS—A Critical Review

  2022cites this paper
• Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives

  2018cites this paper
• Long‐Term Magnetization Transfer Ratio Evolution in Multiple Sclerosis White Matter Lesions

  2018cites this paper
• Trials of Licenced RRMS DMTs in Progressive MS

  2018cites this paper
• Advanced MRI measures like DTI or fMRI should be outcome measures in future clinical trials – Commentary

  2017cites this paper
• Multiple sclerosis.

  2016cites this paper
• Advanced Structural and Functional Brain MRI in Multiple Sclerosis

  2016cites this paper
• Surrogate Markers in Multiple Sclerosis: The Role of Magnetic Resonance Imaging

  2016cites this paper
• Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse

  2015cites this paper
• Nonconventional MRI and microstructural cerebral changes in multiple sclerosis

  2015cites this paper
• Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

  2015cites this paper
• Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review

  2015cites this paper
• Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?

  2014cites this paper
• Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study

  2014cites this paper
• Disease‐modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

  2014cites this paper
• Rationale for Quantitative MRI of the Human Spinal Cord and Clinical Applications

  2014cites this paper
• Magnetization transfer imaging of acute black holes in patients on glatiramer acetate.

  2012cites this paper
• Disease-modifying therapy for multiple sclerosis in clinical practice

  2011cites this paper
• Magnetic resonance techniques in multiple sclerosis: the present and the future.

  2011cites this paper
• Einsatz intravenöser Immunglobuline in der Neurologie

  2010cites this paper
• Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study

  2010cites this paper
• Use of Imaging in Multiple Sclerosis

  2010cites this paper
• Magnetization transfer MR imaging in multiple sclerosis.

  2009cites this paper
• Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials.

  2009cites this paper
• A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events.

  2009cites this paper
• Hoe zelfvoorziening in stabiele plasmaderivaten voor België verzekeren ?

  2009cites this paper
• NF-B , a Potential Therapeutic Target for the Treatment of Multiple Sclerosis

  2009cites this paper
• The relation between inflammation and neurodegeneration in multiple sclerosis brains

  2009cites this paper
• [Neurodegeneration and neuroprotection in multiple sclerosis].

  2009cites this paper
• Demyelinating Disorders of the Central Nervous System

  2009cites this paper
• A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events

  2009cites this paper
• Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis

  2009cites this paper
• Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives

  2008cites this paper
• NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis.

  2008cites this paper
• Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis

  2008cites this paper
• Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins

  2008cites this paper
• MRI to Monitor Treatment Efficacy in Multiple Sclerosis

  2007cites this paper
• Magnetization Transfer MRI in Multiple Sclerosis

  2007cites this paper
• Intravenous immunoglobulin in MS: promise or failure?

  2007cites this paper
• Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve

  2007cites this paper
• IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions

  2007cites this paper
• Critical Review of Existing Trials

  2007cites this paper
• Measures of magnetization transfer in multiple sclerosis

  2007cites this paper
• EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis

  2006cites this paper
• IVIg attenuates T cell-mediated killing of human neurons.

  2006cites this paper
• EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis

  2006cites this paper
• Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis.

  2006cites this paper
• Current trials in multiple sclerosis: established evidence and future hopes

  2005cites this paper
• MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)

  2005cites this paper
• Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging

  2005cites this paper
• [High-dose intravenous immunoglobulins in the treatment of multiple sclerosis. An update].

  2005cites this paper
• Magnetization Transfer Imaging in Multiple Sclerosis

  2005cites this paper
• Clinical trials in multiple sclerosis: methodological issues

  2005cites this paper
• Imaging of multiple sclerosis: Role in neurotherapeutics

  2005cites this paper
• Normal-Appearing White Matter Changes in Multiple Sclerosis: Magnetization Transfer

  2004cites this paper